Hsa-miR-214-3p and its Role in Breast Cancer
Author Information
Author(s): LU YAN, WANG KANG, PENG YUANHONG, CHEN MENG, ZHONG LIN, HUANG LUJI, CHENG FU, SHENG XINDAN, YANG XIN, OUYANG MANZHAO, CALIN GEORGE A., HE ZHIWEI
Primary Institution: Southern Medical University Shunde Hospital
Hypothesis
Hsa-miR-214-3p could suppress breast cancer cell proliferation and enhance immune cell activity by modulating B7H3 expression.
Conclusion
Hsa-miR-214-3p reduces tumor cell proliferation and improves the tumor immune microenvironment by downregulating B7H3.
Supporting Evidence
- B7H3 expression is inversely correlated with hsa-miR-214-3p levels in breast cancer tissues.
- Hsa-miR-214-3p inhibits breast cancer cell growth by downregulating B7H3.
- Co-culture experiments show that hsa-miR-214-3p enhances CD8+ T cell and NK cell activity.
- Hsa-miR-214-3p has two binding sites on the 3’ UTR of B7H3.
Takeaway
This study shows that a tiny molecule called hsa-miR-214-3p can help fight breast cancer by stopping cancer cells from growing and helping the body's immune system work better.
Methodology
The study analyzed B7H3 expression in breast cancer samples, used dual-luciferase reporter assays to investigate hsa-miR-214-3p's regulatory role, and performed in vitro experiments to assess effects on cell proliferation and immune response.
Limitations
The study did not identify the receptors and binding partners of B7H3, which limits targeted therapy development.
Participant Demographics
20 patients with breast cancer from Shunde Hospital, Southern Medical University.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website